No CCS News over Easter break

Due to the extended Easter / ANZAC Day break, the next CCS News will go out on Friday 10th May. Enjoy the break everyone!

Promising technology heads to Melbourne for Parkinson's Disease trial

The Reviver in action

Technology being brought to Melbourne as part of a trial by Neuroscience researcher Dr Ben Sinclair made the Sydney news recently. The Reviver is a device that tilts people and rotates them through the gravitational field, strengthening muscles with minimal conscious effort. In people with neuromuscular degenerative conditions like Multiple Sclerosis and Parkinson's Disease, it stimulates remaining reflex pathways, providing better muscle tone and balance.

Inaugural Monash-wide immunology symposium

Dr Emily Edwards from our Department of Immunology and Pathology is on the organising committee of ImmuMon 2019, the first annual symposium to promote networking and collaboration among immunology researchers across Monash University. It will be held on 7th June 2019 at the former Alfred Research Alliance lecture theatre, 75 Commercial Road, Melbourne.

Translational Research Symposium Speaker Spotlight: Doctor Joshua Ooi

Dr Joshua Ooi

Monash University's 5th annual Translational Research Symposium is being hosted by its three metropolitan clinical schools on 21 June 2019. The symposium will host a diverse group of medical researchers presenting their work into translational research. RSVP here.

Doctor Joshua Ooi is a senior research fellow in the Centre of Inflammatory Diseases at Monash Health.

CCS Recent Publications: 3rd - 9th April

Recent publications for Central Clinical School feature affiliated authors in the following departments:

Prof. Robyn O'Hehir AO had two articles published this week.

• Neuroscience
• MAPrc
• Peninsula Clinical School
• Anaesthesia and Perioperative Medicine
• Melbourne Sexual Health Centre
• Gastroenterology
• Australian Centre for Blood Diseases
• Diabetes
• AIRmed

Study finds drug link to harmful diabetic complication

Surgery and fasting were associated with a higher risk
of DKA in inpatients

by Anne Crawford

Diabetic ketoacidosis (DKA) is a serious and potentially life-threatening medical condition.
It is associated with very high blood glucose levels and insufficient insulin in the blood, which forces the body to burn fat for energy and leads to a build-up of dangerous chemical substances called ketones in the blood.

DKA occurs mostly in people with type 1 diabetes; those with type 2 diabetes develop it very rarely and usually in the context of severe stress.

However, in the past few years clinicians treating people with type 2 diabetes across Melbourne have noticed that some were developing the condition after being administered oral antidiabetic drugs called sodium-glucose cotransporter 2 inhibitors (SGLT2i).

A/Prof White inducted as NANOS Fellow

A/Prof Owen White, co-lead of the School's Ocular Motor Research group, has been inducted as a Fellow of the North American Neuro-Ophthalmology Society (NANOS) in recognition of his substantial contribution to NeuroOpthalmology.

Fellows must be board certified in their specialty, have a chief interest and specialty training in Neuro-Ophthalmology, be an active member of NANOS, and demonstrate special achievement in clinical NeuroOphthalmology.